News | March 19, 2026
Mankind Pharma acquires Rivotril brand for India
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The entire integration and transition of the brands is expected to be completed by March 2022
Subscribe To Our Newsletter & Stay Updated
